ASSESSMENT OF THE EXPERIENCE OF PROVIDING REHABILITATION SERVICES BASED ON THE ANALYSIS OF THE “COST OF ILLNESS”
key basis for any product cost proposal and market access activity. Analysis of the “cost of disease” and publications using this method are important tools to increase the awareness of payers of the cost of disease conditions for health systems and society. The results of this analysis are useful in discussing public policy issues and can help policy makers determine where funding should be concentrated.
Purpose: to analyze the "cost of the disease" at the rehabilitation level based on data from the "East Kazakhstan Regional Rehabilitation Center"
Materials and research methods. The study evaluated rehabilitation services using the Cost of Illness (COI) analysis-based method. This indicator is calculated by the formula direct medical costs + indirect medical costs + indirect costs. The data for the analysis of direct medical rehabilitation costs were taken from RSE at RVP "East Kazakhstan Rehabilitation Center" for 2019. The data were presented in M (SD), Me (Q1, Q3), the calculations were carried out in SPSS for Windows version 20.0.
The results of the study. The most expensive group in need of rehabilitation is the group Z 92.5 “In a personal history of rehabilitation procedures”. In general, there is a high variability of costs in tenge both within groups and between groups (m (SD); Me (Q1, Q3)): 84408 (14399), 88433 (13473), 49603 (11824), 58742 (54189, 64876) . Nevertheless, the actual cost of a patient's stay in bed days is significantly higher and amounts to 183218 tenge per month. Temporary inconvenience costs 89180 tenge per year for 1 person in need of rehabilitation. Despite the low number of people with disabilities among patients (less than 5%), indirect costs for payments may vary, depending on the disability group, from 30,886 to 57021 tenge per month.
Findings. Evaluation by analysis of the “cost of the disease” method allows decision-makers to create conditions for further analytical work in order to reduce the burden of disease.
Tolkyn M. Sekeeva 1
1 NPJSC "Semey Medical University", Semey, Republic of Kazakhstan.
1. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Колбин А.С., Рафальский В.В., Чеберда А.Е., Кантемирова М.А., Закиев В.Д., Фаеев В.В. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты Российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2 // Сахарный диабет. 2017. Т. 20. №6. С. 403-419.
2. Зеленова О.В., Абрамов С.И., Крекнина Е.А., Зеленова Е.Г. Социальная стоимость болезни – новые возможности для принятия решения на примере прямых затрат терапии осложнений сахарного диабета 2-го типа // Раны и раневые инфекции. Журнал им. проф. Б. М. Костючёнка. 2017. №4. С. 6-13.
3. Кабакова Т.И., Попов А.В., Давидов С.Б., Гончарова Л.В. Фармакоэкономический анализ лечения стационарных больных неврологического профиля, пострадавших в чрезвычайных ситуациях // Фармацевтические науки. 2014. №6. С. 109-112.
4. Ягудина Р.И., Зинчук И.Ю., Литвиненко М.М. Анализ «Стоимости болезни»: виды, методология, особенности проведения в Российской Федерации // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2012. №1. С. 4-9.
5. Abdo R.R. et al. Direct Medical Cost of Hospitalization for Acute Stroke in Lebanon: A Prospective Incidence-Based Multicenter Cost-of-Illness Study // INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2018. Т. 55. С. 004695801879297.
6. Brodszky V. et al. Cost-of-illness studies in nine Central and Eastern European countries // The European Journal of Health Economics. 2019. Т. 20. № S1. С. 155–172.
7. Clabaugh G., Ward M.M. Cost-of-Illness Studies in the United States: A Systematic Review of Methodologies Used for Direct Cost // Value in Health. 2008. Т. 11. № 1. С. 13–21.
8. Eeden M.V. et al. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke // BMJ Open. 2015. Т. 5. № 11. S.11-22.
9. Ernstsson O. et al. Cost of Illness of Multiple Sclerosis - A Systematic Review // Plos One. 2016. Т. 11. № 7. S. 45-52.
10. Fattore G. et al. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study // BMC Neurology. 2012. Т. 12. № 1. S. 21-29
11. Hejazi S.A. et al. Cost of post-stroke outpatient care in Malaysia // Singapore Medical Journal. 2015. Т. 56. № 02. С. 116–119.
12. Jo C. Cost-of-illness studies: concepts, scopes, and methods // Clinical and Molecular Hepatology. 2014. Т. 20. № 4. С. 327.
13. Luengo-Fernandez R. et al. Economic burden of stroke across Europe: A population-based cost analysis // European Stroke Journal. 2019. Т. 5. № 1. С. 17–25.
14. Raj R., Bendel S. et al. Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study // Critical Care. 2018. №2. С. 44-51.
15. Vincent Y., Leighton C., Kadir J. The Incidence, Prevalence, Costs and Impact on Disability of Common Conditions Requiring Rehabilitation in the US: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Limb Loss, and Back Pain // Arch Phys Med Rehabil. 2014. №5. С. 986-995.
References:
1. Dedov I.I., Kalashnikova M.F., Belousov D.Yu., Kolbin A.S., Rafal'skiy V.V., Cheberda A.E., Kantemirova M.A., Zakiev V.D., Faeev V.V. Analiz stoimosti bolezni sakharnogo diabeta 2 tipa v Rossiyskoy Federatsii: rezul'taty Rossiyskogo mnogotsentrovogo nablyudatel'nogo farmakoepidemiologicheskogo issledovaniya FORSAYT-SD2 [Cost analysis of type 2 diabetes mellitus disease in the Russian Federation: results of the Russian multicenter observational pharmacoepidemiological study FORSIGHT-SD2]. Sakharnyy diabet. [Diabetes mellitus] 2017. T. 20. №6. pp. 403-419.
2. Zelenova O.V., Abramov S.I., Kreknina E.A., Zelenova E.G. Sotsial'naya stoimost' bolezni – novye vozmozhnosti dlya prinyatiya resheniya na primere pryamykh zatrat terapii oslozhneniy sakharnogo diabeta 2-go tipa. [The social cost of the disease - new opportunities for decision making on the example of the direct costs of the treatment of complications of type 2 diabetes]. Rany i ranevye infektsii. Zhurnal im. prof. B. M. Kostyuchenka. [Wounds and wound infections. Magazine them. prof. B. M. Kostyuchenka] 2017. №4. pp. 6-13.
3. Kabakova T.I., Popov A.V., Davidov S.B., Goncharova L.V. Farmakoekonomicheskiy analiz lecheniya statsionarnykh bol'nykh nevrologicheskogo profilya, postradavshikh v chrezvychaynykh situatsiyakh [Pharmacoeconomic analysis of the treatment of inpatients with a neurological profile who suffered in emergency situations]. Farmatsevticheskie nauki. [Pharmaceutical Sciences] 2014. №6. pp. 109-112.
4. Yagudina R. I., Zinchuk I. Yu., Litvinenko M. M. Analiz «Stoimosti bolezni»: vidy, metodologiya, osobennosti provedeniya v Rossiyskoy Federatsii [Analysis of the “Cost of the disease”: types, methodology, features of the conduct in the Russian Federation]. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. [Modern pharmacoeconomics and pharmacoepidemiology] 2012. №1. pp. 4-9.
5. Abdo R.R. et al. Direct Medical Cost of Hospitalization for Acute Stroke in Lebanon: A Prospective Incidence-Based Multicenter Cost-of-Illness Study // INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2018. T. 55. pp. 004695801879297.
6. Brodszky V. et al. Cost-of-illness studies in nine Central and Eastern European countries. The European Journal of Health Economics. 2019. T. 20. № S1. pp. 155–172.
7. Clabaugh G., Ward M.M. Cost-of-Illness Studies in the United States: A Systematic Review of Methodologies Used for Direct Cost. Value in Health. 2008. T. 11. № 1. pp. 13–21.
8. Eeden M.V. et al. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke. BMJ Open. 2015. T. 5. № 11. pp.11-22.
9. Ernstsson O. et al. Cost of Illness of Multiple Sclerosis - A Systematic Review. Plos One. 2016. T. 11. № 7. pp. 45-52.
10. Fattore G. et al. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study. BMC Neurology. 2012. T. 12. № 1. pp. 21-29.
11. Hejazi S.A. et al. Cost of post-stroke outpatient care in Malaysia. Singapore Medical Journal. 2015. T. 56. № 02. pp. 116–119.
12. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clinical and Molecular Hepatology. 2014. T. 20. № 4. pp. 327.
13. Luengo-Fernandez R. et al. Economic burden of stroke across Europe: A population-based cost analysis. European Stroke Journal. 2019. T. 5. № 1. pp. 17–25.
14. Raj R., Bendel S. et al. Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study. Critical Care. 2018. №2. pp. 44-51.
15. Vincent Y., Leighton C., Kadir J. The Incidence, Prevalence, Costs and Impact on Disability of Common Conditions Requiring Rehabilitation in the US: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Limb Loss, and Back Pain // Arch Phys Med Rehabil. 2014. №5. pp. 986-995.
Number of Views: 200
Category of articles:
Original articles
Bibliography link
Sekeeva T.M. Assessment of the experience of providing rehabilitation services based on the analysis of the “cost of illness” // Nauka i Zdravookhranenie [Science & Healthcare]. 2020, (Vol.22) 3, pp. 119-126. doi 10.34689/SH.2020.22.3.015Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS